The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Interest Expense
Cost of servicing the company's debt during the period.
The Chemours CompanyNYSE: CC
Interest Expense · Q2 FY2026 · quarter ended Jun 2026
Interest expense grows in line with its trailing trend
Q2 FY2026 interest expense of $68M rose 3.0% year over year, ahead of the +1.9% change in trailing-twelve-month interest expense. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +18.2% a year.
Context
- Interest expense amounted to 4.6% of revenue in FY2025, unchanged from a year earlier.
- Interest expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3.0% holds above the trailing-twelve-month pace of +1.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 269M USD
- Year-over-year change
- +1.9%
- 4-year CAGR
- +9.8%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 269M | +1.9% |
| FY2024 | 2024-12-31 | 264M | +26.9% |
| FY2023 | 2023-12-31 | 208M | +27.6% |
| FY2022 | 2022-12-31 | 163M | -11.9% |
| FY2021 | 2021-12-31 | 185M | — |
Interest Expense vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 interest expense of $273M is the 2nd highest of the 19 companies compared; the peer median is $78.1M.
- Its year-over-year change of +1.9% is the 9th highest of 19, against a peer median of -1.6%.
- Interest expense amounts to 4.7% of revenue for CC, versus a peer median of 1.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $500M | -3.1% | +20.9% | 1.6% | |
| LTM Jun 2026 | $273M | +1.9% | +18.2% | 4.7% | |
| LTM Jun 2026 | $268M | -10.4% | +34.2% | 0.8% | |
| LTM Jun 2026 | $255M | +5.4% | +13.0% | 1.6% | |
| LTM Sep 2026 | $220.4M | +3.0% | +7.5% | 1.7% | |
| LTM Jun 2026 | $187M | -32.0% | -12.0% | 1.9% | |
| LTM Jun 2026 | $170M | -14.6% | +11.3% | 3.3% | |
| LTM Aug 2026 | $139.35M | +3.9% | +13.4% | 3.9% | |
| LTM Sep 2026 | $92M | -42.1% | -3.1% | 0.8% | |
| LTM Sep 2026 | $81.2M | +49.3% | +1.4% | 2.3% | |
| LTM Jun 2026 | $75M | +0.0% | +10.7% | 2.1% | |
| LTM Mar 2026 | $64.2M | +27.4% | +16.0% | 3.6% | |
| LTM Jun 2026 | $63.51M | +63.7% | -2.8% | 8.4% | |
| LTM Jun 2026 | $61M | -7.6% | -1.5% | 3.3% | |
| LTM Jun 2026 | $30.93M | +7.3% | +26.7% | 1.8% | |
| LTM Mar 2026 | $29.6M | -29.9% | -2.8% | 3.6% | |
| LTM Sep 2026 | $20.06M | -54.4% | +10.6% | 1.0% | |
| LTM Sep 2026 | $11.17M | -38.8% | +104.8% | 0.7% | |
| LTM Mar 2026 | $181K | +30.2% | +6.1% | 0.2% | |
| Peer median (excluding CC) | $78.1M | -1.6% | +10.6% | 1.8% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.